Clinical and Jaw Tracking Assessment Following Intra-articular Injection of PRP and HA in TMJ Disc Displacement With Reduction

September 2, 2026 updated by: Eslam Elbatal, Mansoura University

Biomechanical Assessment of Platelet Rich Plasma and Hyaluronic Acid Intra-articular Injection in Temporomandibular Joint Internal Derangement Using a Jaw Tracking Device

Assessment of intra-articular injection of hyaluronic acid and prp within TMJ using the Zebris jaw tracking device as an objective method

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
    • Dakahlia Governorate
      • Al Mansurah, Dakahlia Governorate, Egypt, 35516
        • Faculty of Dentistry, Mansoura University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria

  1. The patients' ages range from 18 to 45.
  2. Patients experienced clicking sounds, painful joints, and restricted mouth opening.
  3. Individuals whose MRI confirms a unilateral internal abnormality with reduction.
  4. A patient who did not respond to conservative treatment. 5 • The patient's capacity and willingness to finish the course of therapy and subsequent appointments.

Exclusion Criteria

  1. A patient suffering from a connective tissue or inflammatory condition.
  2. A patient who has had TMJ surgery in the past.
  3. A history of injecting any kind of material into the target TMJ.
  4. Drug allergy history.
  5. A patient who has previously had fibrous or bony adhesion.
  6. A patient experiencing psychological issues.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Hyaluronic acid + PRP
patients with disc displacement with reduction will undergo intra-articular injection with hyaluronic acid and prp
Combination product: Hyaluronic Acid (HA) and Platelet rich plasma
A combination of Autologous Platelet-Rich Plasma prepared from the patient's blood and hyaluronic acid injected intra-articularly

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mandibular movements assessed using the zebris JMA
Time Frame: Baseline, 1month
changes in mandibular movements assessed using the Zebris Jaw Motion Analyzer (JMA) system following treatment
Baseline, 1month

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
clicking sound
Time Frame: Baseline, 6 months
changes in clicking sound following treatment
Baseline, 6 months
Pain Assessment using the Visual Analogue Scale
Time Frame: baseline, 1 week, 1 month, 3months, 6 months
Changes in pain intensity assessed using the Visual Analog Scale (VAS), a 0-10 scale where 0 indicates no pain and 10 indicates the worst imaginable pain; higher scores indicate greater pain severity. Measurements will be obtained at baseline, 1 week, 1 month, 3 months, and 6 months following intra-articular injection of hyaluronic acid and platelet-rich plasma (PRP) in patients with temporomandibular joint disc displacement with reduction.
baseline, 1 week, 1 month, 3months, 6 months
MRI assessment of the temporomandibular joint
Time Frame: At baseline and 6 months after treatment
MRI assessment of the temporomandibular joint, including disc position and retrodiscal tissue changes,
At baseline and 6 months after treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Mansoura University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2025

Primary Completion (Actual)

November 15, 2025

Study Completion (Actual)

May 5, 2026

Study Registration Dates

First Submitted

June 7, 2026

First Submitted That Met QC Criteria

June 7, 2026

First Posted (Actual)

June 11, 2026

Study Record Updates

Last Update Posted (Actual)

September 8, 2026

Last Update Submitted That Met QC Criteria

September 2, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MS.25.03.12

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe